Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Liontown Resources Limited

LTR

Liontown Resources Ltd. engages in the exploration and evaluation of minerals. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-27. The firm controls two major hard rock lithium deposits. The firm's projects include Kathleen Valley Project and Buldania Project. The Kathleen Valley Project is located in an established mining region about 60 kilometers north of Leinster and 680 kilometers north-east of Perth, Western Australia. The Kathleen Valley Lithium Project is a Tier-1 battery metals asset with excellent grade and scale in one of world's best mining districts. The Buldania Project is in the Eastern Goldfields Province of Western Australia, approximately 600 kilometers east of Perth. The Project is close to major road and rail infrastructure with direct access to the Port of Esperance 200 kilometers to the south. The firm's downstream expansion project includes investigating the potential for an integrated refinery to upgrade its spodumene from the Kathleen Valley mine to higher value lithium products.

Vanguard MSCI Index International Shares ETF

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

iShares S&P 500 ETF

IVV

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

CSL Limited

CSL

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 32,065 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.